Makers of anticancer drugs are “profiteering,” say 100 specialists from around the world

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f2810 (Published 30 April 2013)
Cite this as: BMJ 2013;346:f2810

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jeremy Laurance
  1. 1The Independent

More than 100 specialists in chronic myeloid leukaemia from around the world, including nine from the United Kingdom, have warned that the high prices that drug companies charge for anticancer drugs are leaving patients without access to treatments that could save their lives.

The group said that the drug industry was guilty of “profiteering” and compared its actions to those of unethical speculators who raise the price of grain after a natural disaster.

“What determines a morally justifiable ‘just price’ for a cancer drug?” they asked in a paper published in Blood.1 “A reasonable drug …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL